Hendrik Setia Budi

Dr. Hendrik Setia Budi

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2022 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
HBHendrik Setia Budi
Hendrik Setia Budi
FAFirdaus Nuri Ahmad
Firdaus Nuri Ahmad
HAHarun Achmad
Harun Achmad
Mohammad Javed AnsariMohammad Javed Ansari
Mohammad Javed Ansari
MMMaria Vladimirovna Mikhailova
Maria Vladimirovna Mikhailova
FMFaroogh Marofi
Faroogh Marofi
Due to the overexpression or amplification of human epidermal growth factor receptor 2 (HER2) with poor prognosis in a myriad of human tumors, recent studies have focused on HER2-targeted therapies. Deregulation in HER2 signaling pathways is accompanied by sustained tumor cells growth concomitant with their migration and also tumor angiogenesis and metastasis by stimulation of proliferation of a network of blood vessels. A large number of studies have provided clear evidence that the emerging HER2-directed treatments could be the outcome of patients suffering from HER2 positive breast and also gastric/gastroesophageal cancers. Thanks to its great anti-tumor competence, immunotherapy using HER2-specific chimeric antigen receptor (CAR) expressing immune cell has recently attracted increasing attention. Human T cells and also natural killer (NK) cells can largely be found in the tumor microenvironment, mainly contributing to the tumor immune surveillance. Such properties make them perfect candidate for genetically modification to express constructed CARs. Herein, we will describe the potential targets of the HER2 signaling in tumor cells to clarify HER2-mediated tumorigenesis and also discuss recent findings respecting the HER2-specific CAR-expressing immune cells (CAR T and CAR NK cell) for the treatment of HER2-expressing tumors.

29 January 2022 in International Immunopharmacology
Verified
Journal Article
Closed access
GUNAWAN WIDJAJAGUNAWAN WIDJAJA
GUNAWAN WIDJAJA
Abduladheem Turki JalilAbduladheem Turki Jalil
Abduladheem Turki Jalil
HBHendrik Setia Budi
Hendrik Setia Budi
Walid KamalWalid Kamal
Walid Kamal
SESyahril Efendi
Syahril Efendi
AYAlexei Valerievich Yumashev
Alexei Valerievich Yumashev

23 May 2023 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
HBHendrik Setia Budi
Hendrik Setia Budi
BFBagher Farhood
Bagher Farhood
Oral cancers are among the common head and neck malignancies. Different anticancer therapy modalities such as chemotherapy, immunotherapy, radiation therapy, and also targeted molecular therapy may be prescribed for targeting oral malignancies. Traditionally, it has been assumed that targeting malignant cells alone by anticancer modalities such as chemotherapy and radiotherapy suppresses tumor growth. In the last decade, a large number of experiments have confirmed the pivotal role of other cells and secreted molecules in the tumor microenvironment (TME) on tumor progression. Extracellular matrix and immunosuppressive cells such as tumor-associated macrophages, myeloid-derived suppressor cells (MDSCs), cancer-associated fibroblasts (CAFs), and regulatory T cells (Tregs) play key roles in the progression of tumors like oral cancers and resistance to therapy. On the other hand, infiltrated CD4 + and CD8 + T lymphocytes, and natural killer (NK) cells are key anti-tumor cells that suppress the proliferation of malignant cells. Modulation of extracellular matrix and immunosuppressive cells, and also stimulation of anticancer immunity have been suggested to treat oral malignancies more effectively. Furthermore, the administration of some adjuvants or combination therapy modalities may suppress oral malignancies more effectively. In this review, we discuss various interactions between oral cancer cells and TME. Furthermore, we also review the basic mechanisms within oral TME that may cause resistance to therapy. Potential targets and approaches for overcoming the resistance of oral cancers to various anticancer modalities will also be reviewed. The findings for targeting cells and potential therapeutic targets in clinical studies will also be reviewed.


1 January 2024 in Brazilian Journal of Biology
Verified
Journal Article
Open access
PDF file
HBHendrik Setia Budi
Hendrik Setia Budi
MJMadiha Fouad Jameel
Madiha Fouad Jameel
GUNAWAN WIDJAJAGUNAWAN WIDJAJA
GUNAWAN WIDJAJA
MAMukhalled Salim Alasady
Mukhalled Salim Alasady
Trias MahmudionoTrias Mahmudiono
Trias Mahmudiono
MKMaria Vladimirovna Kuznetsova
Maria Vladimirovna Kuznetsova
Nanoparticles (NPs) are insoluble particles with a diameter of fewer than 100 nanometers. Two main methods have been utilized in orthodontic therapy to avoid microbial adherence or enamel demineralization. Certain NPs are included in orthodontic adhesives or acrylic resins (fluorohydroxyapatite, fluorapatite, hydroxyapatite, SiO2, TiO2, silver, nanofillers), and NPs (i.e., a thin layer of nitrogen-doped TiO2 on the bracket surfaces) are coated on the surfaces of orthodontic equipment. Although using NPs in orthodontics may open up modern facilities, prior research looked at antibacterial or physical characteristics for a limited period of time, ranging from one day to several weeks, and the limits of in vitro studies must be understood. The long-term effectiveness of nanotechnology-based orthodontic materials has not yet been conclusively confirmed and needs further study, as well as potential safety concerns (toxic effects) associated with NP size.

1 January 2022
Verified
Journal Article
Closed access
HBHendrik Setia Budi
Hendrik Setia Budi
SAS. Anitasari
S. Anitasari
NUN. M. Ulfa
N. M. Ulfa
MSM. A. Setiabudi
M. A. Setiabudi
RRR. Ramasamy
R. Ramasamy
Yung-Kang ShenYung-Kang Shen
Yung-Kang Shen